JP2003522193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522193A5 JP2003522193A5 JP2001558059A JP2001558059A JP2003522193A5 JP 2003522193 A5 JP2003522193 A5 JP 2003522193A5 JP 2001558059 A JP2001558059 A JP 2001558059A JP 2001558059 A JP2001558059 A JP 2001558059A JP 2003522193 A5 JP2003522193 A5 JP 2003522193A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- delivery system
- poly
- integer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 description 36
- 150000002632 lipids Chemical class 0.000 description 26
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 229940088679 drug related substance Drugs 0.000 description 11
- 229920000954 Polyglycolide Polymers 0.000 description 10
- 229920000747 poly(lactic acid) Polymers 0.000 description 10
- 125000001931 aliphatic group Chemical group 0.000 description 9
- 125000000962 organic group Chemical group 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 7
- 102000015439 Phospholipases Human genes 0.000 description 7
- 108010064785 Phospholipases Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 229920006187 aquazol Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 150000008103 phosphatidic acids Chemical class 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- -1 polymethoxazoline Polymers 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 125000005641 methacryl group Chemical group 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 150000007524 organic acids Chemical group 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000211 | 2000-02-10 | ||
| DK200000211 | 2000-02-10 | ||
| DKPA200000616 | 2000-04-12 | ||
| DK200000616 | 2000-04-12 | ||
| PCT/DK2001/000092 WO2001058910A2 (en) | 2000-02-10 | 2001-02-09 | Lipid-based drug delivery systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003522193A JP2003522193A (ja) | 2003-07-22 |
| JP2003522193A5 true JP2003522193A5 (https=) | 2008-04-03 |
Family
ID=26068763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001558059A Pending JP2003522193A (ja) | 2000-02-10 | 2001-02-09 | ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1254143B1 (https=) |
| JP (1) | JP2003522193A (https=) |
| AT (1) | ATE277935T1 (https=) |
| AU (1) | AU778659B2 (https=) |
| CA (1) | CA2399821A1 (https=) |
| DE (1) | DE60105977T2 (https=) |
| ES (1) | ES2230268T3 (https=) |
| PT (1) | PT1254143E (https=) |
| WO (1) | WO2001058910A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2272768T3 (es) * | 2001-10-03 | 2007-05-01 | Celator Pharmaceuticals Inc | Composiciones para la administracion de combinaciones de farmacos. |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| ATE418966T1 (de) * | 2004-11-03 | 2009-01-15 | Liplasome Pharma As | Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid- derivaten und ihre therapeutische verwendung |
| WO2006086992A2 (en) * | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| EP1940355B1 (en) | 2005-09-30 | 2012-12-19 | Auburn University | Targeted drug delivery nanocarrier comprising a targeting landscape phage protein assembly |
| CA2647779A1 (en) * | 2006-03-23 | 2007-09-27 | Liplasome Pharma A/S | Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis |
| EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| DK177532B1 (en) * | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| DK177529B1 (en) * | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
| EP2343310A1 (en) | 2010-01-08 | 2011-07-13 | Novozymes A/S | Serine hydrolase formulation |
| WO2011098578A2 (en) | 2010-02-12 | 2011-08-18 | Bioneer A/S | Liposome system for ocular administration |
| CZ308596B6 (cs) * | 2017-04-03 | 2020-12-23 | Ústav molekulární genetiky AV ČR, v. v. i. | Deriváty fosfolipidů a jejich použití jako léčiva |
| EP3530266A1 (en) | 2018-02-27 | 2019-08-28 | LipoCoat B.V. | A lipid-based coating composition, and an object having a lipid-based coating |
| EP3530265A1 (en) * | 2018-02-27 | 2019-08-28 | LipoCoat B.V. | Universal method for the preparation of lipid-based coatings |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4622392A (en) * | 1984-06-21 | 1986-11-11 | Health Research Inc. (Roswell Park Division) | Thiophospholipid conjugates of antitumor agents |
| US5153000A (en) * | 1988-11-22 | 1992-10-06 | Kao Corporation | Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome |
| JPH07126166A (ja) * | 1993-10-29 | 1995-05-16 | Sagami Chem Res Center | ホスホリパ−ゼａ２阻害剤 |
| JP3498336B2 (ja) * | 1993-12-06 | 2004-02-16 | 日本油脂株式会社 | リン脂質誘導体 |
| JP3620059B2 (ja) * | 1994-03-04 | 2005-02-16 | 日本油脂株式会社 | 反応性小胞体、形成剤および機能性物質固定化小胞体 |
| DE4408011C1 (de) * | 1994-03-10 | 1995-11-02 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Tumortherapie |
| US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
| JP3778528B2 (ja) * | 1996-11-08 | 2006-05-24 | 三菱化学株式会社 | ミセルに組み込まれた水溶性高分子物質の分析方法 |
| US5827836A (en) * | 1996-11-15 | 1998-10-27 | Clarion Pharmaceuticals Inc. | Retinoid glycerol phospholipid conjugates |
| US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
-
2001
- 2001-02-09 EP EP01903609A patent/EP1254143B1/en not_active Expired - Lifetime
- 2001-02-09 CA CA002399821A patent/CA2399821A1/en not_active Abandoned
- 2001-02-09 DE DE60105977T patent/DE60105977T2/de not_active Expired - Lifetime
- 2001-02-09 ES ES01903609T patent/ES2230268T3/es not_active Expired - Lifetime
- 2001-02-09 AU AU31533/01A patent/AU778659B2/en not_active Ceased
- 2001-02-09 JP JP2001558059A patent/JP2003522193A/ja active Pending
- 2001-02-09 EP EP04015791A patent/EP1484332A3/en not_active Withdrawn
- 2001-02-09 AT AT01903609T patent/ATE277935T1/de not_active IP Right Cessation
- 2001-02-09 PT PT01903609T patent/PT1254143E/pt unknown
- 2001-02-09 WO PCT/DK2001/000092 patent/WO2001058910A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003522193A5 (https=) | ||
| US8765181B2 (en) | Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids | |
| JP2003528808A5 (https=) | ||
| US20150283077A1 (en) | Controlled release hydrogels | |
| HUP0202177A2 (hu) | Neutrális lipopolimer és ilyen lipopolimert tartalmazó liposzómakészítmények | |
| WO2009131794A1 (en) | Opioid-ketamine and norketamine codrug combinations for pain management | |
| KR19990087477A (ko) | 완충된 오르쏘 에스테르 중합체를 포함하는 약학 조성물 | |
| KR20020063875A (ko) | 핵산 및 약물 전달용 중성-양이온성 지질 | |
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| KR20130062953A (ko) | 안티센스 올리고뉴클레오티드를 포함하는 약학 조성물 및 이의 사용 방법 | |
| JP2924179B2 (ja) | グリセロール誘導体，デバイス及び医薬組成物 | |
| JP2024512770A (ja) | 遺伝子送達における非ウイルスベクターとしての樹状構造 | |
| JP2003522193A (ja) | ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用 | |
| JP2018526434A (ja) | 緑内障用の徐放性薬物配合物 | |
| US20220226499A1 (en) | Metabolite Delivery for Modulating Metabolic Pathways of Cells | |
| CN115337267A (zh) | 一种基于脂质体纳米囊泡的酸响应型药物递送平台的制备方法及其应用 | |
| WO2006048017A8 (en) | Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof | |
| JP2002518506A5 (https=) | ||
| EP2158908B1 (en) | Composition for transdermal administration | |
| US20210317071A1 (en) | Ph-responsive lipids | |
| CN109276541A (zh) | 一种可调节药物释放的脂质体组合物及其制备方法 | |
| JPH05339152A (ja) | 皮膚病変局所投与薬剤含有キトサン誘導体フィルム剤 | |
| WO2020002056A1 (en) | Cis-oxoplatin for treating stomach cancer | |
| JP2009530318A (ja) | 加水分解時に分子内環化反応を行うホスホリパーゼａ２分解性脂質を含む脂質ベース薬剤送達系 | |
| KR101771786B1 (ko) | 서방성 구강 약물 전달체 |